Describe the effects of conjugated estrogens/bazedoxifene ( CE/BZA ) , a new treatment for vasomotor symptoms ( VMS ) and osteoporosis prevention , on menopause-specific quality of life ( MSQOL ) across different patient population types in phase @ clinical trials .